These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33162995)

  • 1. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
    O'Riordan CE; Purvis GSD; Collotta D; Krieg N; Wissuwa B; Sheikh MH; Ferreira Alves G; Mohammad S; Callender LA; Coldewey SM; Collino M; Greaves DR; Thiemermann C
    Front Immunol; 2020; 11():581758. PubMed ID: 33162995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase (BTK) inhibitors alter blood glucose and insulin in obese mice but reduce inflammation independent of BTK.
    Chan DY; Barra NG; Fang H; Rodrigues E-Lacerda R; Schertzer JD
    Am J Physiol Endocrinol Metab; 2024 Sep; 327(3):E271-E278. PubMed ID: 39017678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury.
    Farahany J; Tsukasaki Y; Mukhopadhyay A; Mittal M; Nepal S; Tiruppathi C; Malik AB
    Am J Respir Cell Mol Biol; 2022 Feb; 66(2):183-195. PubMed ID: 34706199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
    Ghosh S; Mohammed Z; Singh I
    J Neuroinflammation; 2021 Dec; 18(1):289. PubMed ID: 34895246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
    Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Alqahtani F; Alanazi WA; Mahmood HM; Alsanea S; Attia SM
    Int Immunopharmacol; 2021 Jan; 90():107123. PubMed ID: 33168411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia.
    de Porto AP; Liu Z; de Beer R; Florquin S; Roelofs JJTH; de Boer OJ; den Haan JMM; Hendriks RW; van 't Veer C; van der Poll T; de Vos AF
    Front Immunol; 2021; 12():723967. PubMed ID: 34552589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
    Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
    Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice.
    Kawata K; Hatano S; Baba A; Imabayashi K; Baba Y
    Front Immunol; 2024; 15():1388947. PubMed ID: 38638439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
    Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
    Front Immunol; 2018; 9():2027. PubMed ID: 30237801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
    Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.
    Kim C; Park JH; Choi YJ; Jun HO; Chung JK; Park TK; Yoon JS; Yang JW; Jang SY
    Front Endocrinol (Lausanne); 2024; 15():1420024. PubMed ID: 39280007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
    Benner B; Carson WE
    J Hematol Oncol; 2021 Jan; 14(1):15. PubMed ID: 33441177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.